Immix BioPharma Successfully Produces Third NXC-201 Engineering Batch at U.S. CAR-T Manufacturing Facility
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Facility LOS ANGELES, Oct. 16, 2023 Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of NXC-201 at its state-of-the-art cellular immunotherapy manufacturing facility in California. This milestone marks a significant step forward in…